Cargando…
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects
Abstract. Objective: Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D. Materials and methods: In this randomized do...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341243/ https://www.ncbi.nlm.nih.gov/pubmed/35770520 http://dx.doi.org/10.5414/CP204180 |
_version_ | 1784760570688307200 |
---|---|
author | Arguelles-Tello, Federico Alberto Kammar-García, Ashuin Trejo-Jasso, Cristian Adolfo Huerta-Cruz, Juan Carlos Barranco-Garduño, Lina Marcela Rocha-González, Héctor Isaac Reyes-García, Juan Gerardo |
author_facet | Arguelles-Tello, Federico Alberto Kammar-García, Ashuin Trejo-Jasso, Cristian Adolfo Huerta-Cruz, Juan Carlos Barranco-Garduño, Lina Marcela Rocha-González, Héctor Isaac Reyes-García, Juan Gerardo |
author_sort | Arguelles-Tello, Federico Alberto |
collection | PubMed |
description | Abstract. Objective: Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D. Materials and methods: In this randomized double-blind study, 137 participants received 1 mg mazindol (n = 65) alone or combined with 500 mg metformin (n = 72), twice a day, for 6 months. Results: Mazindol and mazindol-metformin were similarly effective. However, when subjects were subclassified into non-diabetics and prediabetics, according to glycated hemoglobin (HbA1c) – < 5.7% and 5.7 – 6.4%, respectively – and/or fasting plasma glucose (FPG) – < 100 mg/dL and 100 – 125 mg/dL, respectively –, differences were evident. Prediabetics in the mazindol-metformin group had a higher rate of 7% weight reduction (78.4%, n = 37) compared to prediabetics treated with mazindol (48.3%, n = 29). Furthermore, mazindol-metformin treatment induced significant reductions in fasting plasma insulin, HOMA-IR, and HbA1c in prediabetics compared to mazindol. No differences were found in any parameter between non-diabetics treated with mazindol (n = 36) and mazindol-metformin (n = 35). Conclusion: Our results highlight the effectiveness of mazindol-metformin to achieve higher rates of 7% weight reduction and to improve the glycemic profile in prediabetic obese subjects, which could be useful to prevent or delay T2D in these subjects. |
format | Online Article Text |
id | pubmed-9341243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-93412432022-08-03 Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects Arguelles-Tello, Federico Alberto Kammar-García, Ashuin Trejo-Jasso, Cristian Adolfo Huerta-Cruz, Juan Carlos Barranco-Garduño, Lina Marcela Rocha-González, Héctor Isaac Reyes-García, Juan Gerardo Int J Clin Pharmacol Ther Research Article Abstract. Objective: Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D. Materials and methods: In this randomized double-blind study, 137 participants received 1 mg mazindol (n = 65) alone or combined with 500 mg metformin (n = 72), twice a day, for 6 months. Results: Mazindol and mazindol-metformin were similarly effective. However, when subjects were subclassified into non-diabetics and prediabetics, according to glycated hemoglobin (HbA1c) – < 5.7% and 5.7 – 6.4%, respectively – and/or fasting plasma glucose (FPG) – < 100 mg/dL and 100 – 125 mg/dL, respectively –, differences were evident. Prediabetics in the mazindol-metformin group had a higher rate of 7% weight reduction (78.4%, n = 37) compared to prediabetics treated with mazindol (48.3%, n = 29). Furthermore, mazindol-metformin treatment induced significant reductions in fasting plasma insulin, HOMA-IR, and HbA1c in prediabetics compared to mazindol. No differences were found in any parameter between non-diabetics treated with mazindol (n = 36) and mazindol-metformin (n = 35). Conclusion: Our results highlight the effectiveness of mazindol-metformin to achieve higher rates of 7% weight reduction and to improve the glycemic profile in prediabetic obese subjects, which could be useful to prevent or delay T2D in these subjects. Dustri-Verlag Dr. Karl Feistle 2022-08 2022-06-30 /pmc/articles/PMC9341243/ /pubmed/35770520 http://dx.doi.org/10.5414/CP204180 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Arguelles-Tello, Federico Alberto Kammar-García, Ashuin Trejo-Jasso, Cristian Adolfo Huerta-Cruz, Juan Carlos Barranco-Garduño, Lina Marcela Rocha-González, Héctor Isaac Reyes-García, Juan Gerardo Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title_full | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title_fullStr | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title_full_unstemmed | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title_short | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects |
title_sort | metformin improves the weight reduction effect of mazindol in prediabetic obese mexican subjects |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341243/ https://www.ncbi.nlm.nih.gov/pubmed/35770520 http://dx.doi.org/10.5414/CP204180 |
work_keys_str_mv | AT arguellestellofedericoalberto metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT kammargarciaashuin metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT trejojassocristianadolfo metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT huertacruzjuancarlos metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT barrancogardunolinamarcela metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT rochagonzalezhectorisaac metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects AT reyesgarciajuangerardo metforminimprovestheweightreductioneffectofmazindolinprediabeticobesemexicansubjects |